Aspira Women’s Health announced a new agreement with Anthem Blue Cross in California for reimbursement coverage of the Company’s OvaSuiteSM portfolio of risk assessment tests effective June 1 Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California. “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite portfolio, which provides a clear benefit to physicians in their clinical assessment of women with adnexal masses,” said Torsten Hombeck, Chief Financial Officer of Aspira. “This is the first in a series of anticipated agreements with Anthem affiliated members following our successful completion of its credentialing process in March. Our strategic focus on payer adoption continues to gather momentum.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AWH:
- Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
- Aspira Women’s Health files to sell 1.57M shares of common stock for holders
- Aspira Women’s Health price target lowered to $3.30 from $4 at Cantor Fitzgerald
- Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
- Aspira Women’s Health reports Q4 EPS (30c), consensus (45c)